Earnings Recaps

Browse reported earnings of the most popular stocks

Nov 15, 2026 Nov 14, 2026 Nov 13, 2026 Nov 12, 2026 Nov 11, 2026 Nov 10, 2026 Nov 9, 2026 Nov 8, 2026 Nov 7, 2026 Nov 6, 2026 Nov 5, 2026 Nov 4, 2026 Nov 3, 2026 Nov 2, 2026 Nov 1, 2026 Oct 31, 2026 Oct 30, 2026 Oct 29, 2026 Oct 28, 2026 Oct 27, 2026 Oct 26, 2026 Oct 25, 2026 Oct 24, 2026 Oct 23, 2026 Oct 22, 2026 Oct 21, 2026 Oct 20, 2026 Oct 19, 2026 Oct 18, 2026 Oct 17, 2026 Oct 16, 2026 Oct 15, 2026 Oct 14, 2026 Oct 13, 2026 Oct 11, 2026 Oct 10, 2026 Oct 9, 2026 Oct 8, 2026 Oct 7, 2026 Oct 3, 2026 Oct 2, 2026 Oct 1, 2026 Sep 30, 2026 Sep 29, 2026 Sep 27, 2026 Sep 26, 2026 Sep 25, 2026 Sep 24, 2026 Sep 23, 2026 Sep 19, 2026 Sep 18, 2026 Sep 17, 2026 Sep 16, 2026 Sep 14, 2026 Sep 13, 2026 Sep 12, 2026 Sep 11, 2026 Sep 10, 2026 Sep 9, 2026 Sep 8, 2026 Sep 5, 2026 Sep 4, 2026 Sep 3, 2026 Sep 2, 2026 Sep 1, 2026 Aug 31, 2026 Aug 30, 2026 Aug 29, 2026 Aug 28, 2026 Aug 27, 2026 Aug 26, 2026 Aug 25, 2026 Aug 23, 2026 Aug 22, 2026 Aug 21, 2026 Aug 20, 2026 Aug 19, 2026 Aug 18, 2026 Aug 17, 2026 Aug 16, 2026 Aug 15, 2026 Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026
53 companies Today

Allianz SE

ALIZY Q3 2026
Reported: 2026-11-15

Allianz gained 1.4% after reporting nine-month operating profit growth and raising the upper end of its full-year operating profit outlook. The reaction was positive but modest; elevated third-quarter catastrophe claims weighed on P&C, while the transcript does not provide enough detail to assess the full-year outlook against expectations.

Key takeaways
  • Total business volume rose around 4% on an internal basis; nine-month operating profit increased 8%, with growth across all segments.
  • Allianz raised the upper end of its full-year operating profit target range to around €18.6 billion.
  • P&C internal growth was 5%, and the combined ratio was at the lower end of the 92%–93% outlook range. Elevated third-quarter European hailstorm claims were a headwind; the expense ratio improved 30 basis points year on year.
  • Adjusted core net income rose around 7% and core EPS grew 8%; adjusted core ROE was 19%.
  • The solvency ratio was 219%, after market volatility and the acquisition of an additional 5% ownership of PIMCO.

Altius Minerals Corporation

ALS.TO Q3 2026
Reported: 2026-11-15

Shares fell 10.3% after earnings, despite record royalty revenue, as the transcript highlights uncertainty around lithium: prices retreated to below incentivization levels, and Sigma temporarily shut down over permitting issues. The call also noted higher expenses and lower operating cash flow than adjusted EBITDA, though it did not state a specific change to the company’s published outlook.

Key takeaways
  • Q3 royalty revenue reached a record **$33.3 million**; adjusted EBITDA was **$27.1 million**.
  • Net earnings were **$10.1 million, or $0.17 per share**. Adjusted net earnings were **$0.18 per share**; the company cited higher cost of sales, share-based compensation and amortization.
  • Operating cash flow was **$11.8 million**, with higher royalty receipts and interest income offset by higher tax and interest payments and working-capital changes.
  • Lithium developments were mixed: Sigma resumed operations after resolving permitting challenges, while Core expected first production at Finniss in the current quarter. Management said lithium prices had fallen back below incentivization levels.
  • Altius reported **$500 million** in total available liquidity and announced an agreement to acquire TNR Gold, adding a royalty on the Los Azules copper project and consolidating its interest in the Mariana lithium royalty.

Altimmune, Inc.

ALT Q3 2026
Reported: 2026-11-15

Altimmune fell 16.6% after earnings, despite management’s positive framing. The transcript offers no new financial or clinical setback; the likely source of disappointment is the long wait for the pivotal PERFORMA readout, expected in 2029, with enrollment still ramping and ex-U.S. sites yet to activate.

Key takeaways
  • PERFORMA Phase 3 is screening and dosing patients; the majority of planned U.S. sites are active, while ex-U.S. sites are expected to activate over the coming months.
  • The company anticipates PERFORMA’s 52-week data readout in 2029, leaving a lengthy timeline to a key MASH milestone.
  • Management said new 48-week IMPACT data highlighted antifibrotic activity; the study was published in *The Lancet* this week.
  • RECLAIM Phase 2 data in alcohol use disorder were presented as a late-breaking oral presentation; an FDA end-of-Phase 2 meeting is scheduled for next month.
  • Management cited estimates that 55%–94% of alcohol-related liver disease patients also meet criteria for alcohol use disorder, supporting its rationale for developing pemvidutide across both indications.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...